Single-cell based precision oncology: First steps in addressing and overcoming tumor heterogeneity

Shutdown precluded NCI officials from appearing at AACI/CCAF annual meeting

NCI officials were notably absent from the annual meeting of the Association of American Cancer Institutes and the Cancer Center Administrators Forum in Washington, DC, due to the government shutdown that started on Oct. 1.

Cliff Hudis on how AI in cancer care is “inevitable”—and ASCO is working to make it safer

“Our goal was very clear from the beginning, which was to develop a user-friendly simple chat-like interface that would provide specific high-quality answers to questions that our members would bring, utilizing only our content,” said Clifford A. Hudis, CEO of the American Society of Clinical Oncology and executive vice chair of the Conquer Cancer Foundation.

October 22, 2025

Vol.51 No.38

Guest Editorial

Study finds no correlation between cancer burden in catchment areas and cancer centers’ CCSG funding

When the idea of looking at cancer center funding and the cancer burden of cancer center catchment areas came to us in the summer of 2024, we lived in a different context.

October 17, 2025

Vol.51 No.38

By Todd Burus, Caree McAfee and Pamela C. Hull

Drugs & Targets

ARPA-H selects Tempus as contract research organization for ADAPT Program

Tempus AI was selected by the Advanced Research Projects Agency for Health to provide testing and contract research organization services in support of the agency’s Advanced Analysis for Precision Cancer Therapy program.

October 17, 2025

Vol.51 No.38

Drugs & Targets

Algen Biotechnologies, AstraZeneca form AI drug discovery partnership

Algen Biotechnologies and AstraZeneca are entering into a multi-target research collaboration to advance AI-powered drug discovery in immunology.

October 17, 2025

Vol.51 No.38

Clinical Roundup

OSUCCC–James researchers are using AI to better predict, diagnose lobular cancer

Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at the Ohio State University Comprehensive Cancer Center is using artificial intelligence to devise new ways of predicting which patients will develop an aggressive and difficult-to-detect form of breast cancer called lobular cancer, which represents one in every 10 breast cancers diagnosed in the United States.

October 10, 2025

Vol.51 No.37

Single-cell based precision oncology: First steps in addressing and overcoming tumor heterogeneity

YOU MAY BE INTERESTED IN

Shutdown precluded NCI officials from appearing at AACI/CCAF annual meeting

Cliff Hudis on how AI in cancer care is “inevitable”—and ASCO is working to make it safer

Study finds no correlation between cancer burden in catchment areas and cancer centers’ CCSG funding

ARPA-H selects Tempus as contract research organization for ADAPT Program

Algen Biotechnologies, AstraZeneca form AI drug discovery partnership

OSUCCC–James researchers are using AI to better predict, diagnose lobular cancer

Renew today!

Subscriber content

Never miss an issue!

Login